All About Multiple Sclerosis

More MS news articles for March 2003

Gadolinium-enhanced magnetic resonance imaging predicts response methylprednisolone in multiple sclerosis

Multiple Sclerosis, 1 February 2003, vol. 9, no. 1, pp. 102-107(6)
Sellebjerg F.[1]; Jensen C.[2]; Larsson H.[2]; Frederiksen J.[1]
[1] The MS Clinic, Department of Neurology, University of Copenhagen, Glostrup Hospital, DK-2600 Glostrup, Denmark [2] Department of Magnetic Resonance Imaging, University of Copenhagen, Hvidovre Hospital, DK-2630 Hvidovre, Denmark

Oral high-dose methylprednisolone treatment is efficacious in acute optic neuritis (ON) and attacks of multiple sclerosis (MS).

The responses to treatment in subgroups of patients participating in two randomized, controlled trials were assessed.

Fifty-eight patients with ON and 51 patients with attacks of MS were treated with placebo or oral methylprednisolone (500 mg daily for five days with a 10-day tapering period).

A gadolinium (Gd)-enhanced magnetic resonance imaging (MRI) scan was obtained at baseline in 66 patients, and 29 patients underwent repeated MRI studies.

Seventy-four patients underwent lumbar puncture before treatment.

The odds ratio (OR) of improvement after methylprednisolone treatment (a one point change in the visual function system score of the Kurtzke Expanded Disability Status Scale (EDSS) in ON or in the EDSS score in attacks of MS) was higher in patients with enhancing lesions on baseline MRI (one week: OR 15, P =0.02; eight weeks: OR 4.6, P =0.02).

Methylprednisolone treatment suppressed Gd-enhancement after one week (P<0.001) and three weeks (P =0.001).

Cerebrospinal fluid measures of intrathecal inflammation correlated with the area of Gd-enhancement but did not correlate as closely with the treatment response as did the results of Gd-enhanced MRI.

These findings suggest that the resolution of intrathecal inflammation as assessed by Gd-enhanced MRI is a major effect of oral high-dose methylprednisolone.